Decision
The debate reveals a high-risk, high-potential-reward scenario, but the preponderance of evidence, especially when refined by past mistakes, supports a BUY action.
The aggressive analyst correctly identifies that the stock’s current price bakes in much of the known negative sentiment. The neutral analyst provides the crucial, pragmatic framework for action: a defined entry zone, a tight stop, and a clear target. This aligns perfectly with the critical lesson learned from past mistakes: “止损触发率50%>=50%,判定为高风险形态:必须先定止损后开仓” (A 50% stop-loss trigger rate indicates high-risk conditions: a stop-loss must be set before opening a position).
The conservative analyst’s warnings are valid but are best used for risk management parameter setting rather than for justifying total inaction. Their argument that patent risk is not fully priced in is the strongest counterargument, but the 6.3% dividend yield and 14-year growth history provide a tangible margin of safety against a dramatic, immediate collapse. The stock is not in a technical free-fall; it is testing established support levels ($26.09 MA_60, $26.38 Bollinger Lower Band).
Therefore, the recommendation is to BUY, but to do so with the disciplined, risk-first approach dictated by history.